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In patients undergoing extrarenal transplantation, the favorable outcomes associated with 
calcineurin inhibitors (CNI) have been tempered by the negative impact of CNI nephrotoxicity 
(l). This well described phenomenon has led to the development of end stage renal disease 
(ESRD) as an important complication of extrarenal transplantation, and some of these patients 
have gone on to kidney transplantation. A number of centers have reported on the efficacy of 
alemtuzumab induction or preconditioning in patients undergoing kidney transplantation alone (2 
- 10). However, there are no publications describing the utility of alemtuzumab in patients 
undergoing kidney after extrarenal transplantation. In this report, we discuss our single center, 
retrospective experience with alemtuzumab induction, and compare it to a previous cohort not 
receiving alemtuzumab. 
Patients and Methods 
Between May 18, 1998 and October 8, 2007, 144 patients underwent kidney after 
extrarenal transplantation (Table 1). 72 patients received alemtuzumab induction (1 dose of 30 
mg IV or 0.4 - 0.5 mg/kg in pediatric patients), with 2 peri operative doses of steroids, and simple 
resumption of the pre-kidney transplantation immunosuppressive regimen. 72 patients did not 
receive alemtuzumab (or, for the most part, any other antibody induction); they routinely 
received additional induction and maintenance steroids, higher doses of CNls, and the addition 
of an antiproliferative agent (usually MMF) if they had not been on one previously. There were 
133 (92.4%) adults and 11 (7.6%) children. 35 (24.3%) had undergone previous heart, 16 
(11.1%) lung, 87 (60.4%) liver, and 6 (4.2%) multivisceral transplantation. There were 100 
(69.4%) deceased donor transplants, with a mean CIT of 24.7 ± 7.9 hours, and 44 (30.6%) living 
donor cases. Alemtuzumab began to be used in our institution in late 2002, so that the follow-up 
for the alemtuzumab patients was shorter, 23.3 ± 15.0 months, than for the no alemtuzumab 
patients, 48.1 ± 36.9 months. The overall mean follow-up was 35.7 ± 30.7 months. 
Statistics 
Continuous variables were compared using the t-test with Levene's test employed for 
verifying the assumption of equality of variance. The chi-square test was used to compare 
categorical variables. 
Institutional Oversight 
The data analysis was performed on de-identified data by one of the honest brokers in our 
division, Joseph Donaldson, under the guidelines of the IRB protocol number 0505123. (11) 
Results (Table 2) 
Overall 1 and 3 year patient survival was 91.5% and 75.3%, and was 93.0% and 78.9% in 
the alemtuzumab group and 90.0% and 72.4% in the no alemtuzumab group, respectively (p = 
ns). Overall 1 and 3 year graft survival was 88.1 % and 71.4%, and was 93.0% and 75.3% in the 
alemtuzumab group and 83.3% and 68.7% in the no alemtuzumab group, respectively (p = 0.051 
- Figure 1). The overall mean serum creatinine levels at 1 and 3 years were 1.4 + 0.7 mg/dl and 
1.5 + 0.9 mg/dl, respectively, and were not statistically different between the two groups. The 
incidence of acute rejection was lower in the alemtuzumab group, 15.3%, than in the no 
alemtuzumab group, 41.7% (p = 0.0001 - Table 3). The incidence of delayed graft function, defined 
as the need for dialysis during the first week after transplantation, was lower in the alemtuzumab 
group, 9.7%, than in the no alemtuzumab group, 25.0% (p = 0.003 - Table 3). The incidence of 
viral complications was not different between the two groups. 
Discussion 
Kidney after extrarenal transplantation is an uncommon subject for discussion, and the 
approach to immunosuppression is not well defined. In our center, it has accounted for 7.1 % of the 
kidney transplantations that have been performed, with 144/2034 cases in less than 10 years. As the 
kidney is a third party antigen, and as the level of immunosuppression in extrarenal transplants 
recipients tends to be relatively low by the time a kidney transplantation needs to be performed, 
some additional immunosuppression needs to be administered to prevent rejection of the kidney. 
The advantage of alemtuzumab induction in this context is that the baseline immunosuppression 
does not need to be changed. This simplifies patient management after transplantation and has the 
further advantage of less rejection, less DGF and slightly better graft survival, without any increase 
in viral complications. 
There are certain settings in kidney after extrarenal transplantation where alemtuzumab is 
not necessarily a good idea. These would include patients who are hepatitis C (HCY) positive and 
have had a previous liver transplant (12), or recently transplanted patients who have received heavy 
immunosuppression for the extrarenal organ. In these situations, we have recently utilized 
dac1izumab induction 1mg/kg at the time of transplantation and every 2 weeks for 4 additional 
doses, with standard tacrolimus/MMF-based immunosuppression, without additional maintenance 
steroids. This seems anecdotally to be a satisfactory approach. 
This experience has obvious limitations. It is retrospective, not randomized, and the no 
alemtuzumab group is something of an historical control. Unfortunately, kidney after extrarenal 
transplantation is not performed very often, and a randomized trial, either single center or 
multicenter, while desirable, will not be straightforward to perform. In the absence of such a trial, 
the experience reported here suggests that alemtuzumab induction with resumption of pre-kidney 
transplantation immunosuppression represents a simple and effective regimen in patients 
undergoing kidney after extrarenal transplantation. 
Table 1 
No Alemtuzumab 
Overall Alemtuzumab Group Group 
5/18/1998 - 1/15/2003 - 5/18/1998 -
Time 10/8/2007 10/8/2007 7/21/2007 
N 144 72 72 
Recipient Age (yrs.) 52.1 +- 16.6 54.1 +- 15.5 50.1 +-17.5 
Donor Age (yrs.) 38.4 +- 16.5 38.0 +- 15.5 38.9 +-17.6 
Time after Extrarenal Tx (yrs.) 8.1 +- 4.7 8.3 +- 5.1 8.0 +- 4.4 
Adult 133 (92.4%) 68 (94.4%) 65 (90.3%) 
Child 11 (7.6%) 4 (5.6%) 7 (9.7%) 
Previous 
Heart 35 (24.3%) 26 (36.1%) 9 (12.5%) 
Lung 16 (11.1%) 7 (9.7%) 9 (12.5%) 
Liver 87 (60.4%) 37 (51.4%) 50 (69.4%) 
Mu Itivisceral 6 (4.2%) 2 (2.8%) 4 (5.6%) 
Deceased Donor 100 (69.4%) 45 (62.5%) 55 (76.4%) 
Cold Ischemia Time 24.7 +- 7.9 hrs 24.2 +- 7.5 hrs 25.1 +- 8.4 hrs 
Living Donor 44 (30.6%) 27 (37.5%) 17 (23.6%) 
PRA 3.3 +- 9.6 2.6 +- 9.7 4.0 +- 9.4 
Table 2 
No Alemtuzumab 
Overall Alemtuzumab Group Group 
Patient 
1 year Survival % 91.5% 93.0% 90.0% 
3 year Survival % 75.3% 78.9% 72.4% 
Graft 
1 year Survival % 88.1% 93.0% 83.3% 
3 year Survival % 71.4% 75.3%* 68.7% 
Mean Serum Creatinine 
1 year 1.4 +- 0.7 mg/dl 1.3 +- 0.5 mg/dl 1.5 +- 0.8 mg/dl 
3 year 1.5 +- 0.9 mg/dl 1.3 +- 0.7 mg/dl 1.6 +- 1.0 mg/dl 
* p = 0.051 
Table 3 
Overall Alemtuzumab No Alemtuzumab 
Group Group 
Complications 
Acute Rejection 28.5% 15.3% 41.7%** 
Delayed Graft Function 17.4% 9.7% 25.0%*** 
CMV 0% 0% 0% 
PTLD 0.7% 0% 1.4% 
BK Virus 4.2% 4.2% 2.8% 
** p = 0.0001 
*** p = 0.003 
Figure 1 - Graft Survival in Kidney after Extrarenal Transplantation 
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